関節リウマチ治療薬：各種技術と世界市場

世界の関節リウマチ治療薬の市場規模は、2024年の285億米ドル、2025年の302億米ドルから、2025年から2030年までの予測期間中はCAGR 6.3%で推移し、2030年には411億米ドルに達すると予測されています。

北米市場は、2024年の155億米ドル、2025年の164億米ドルから、予測期間中はCAGR 6.4%で推移し、2030年には224億米ドルに達すると予測されています。アジア太平洋地域市場は、2024年の42億米ドル、2025年の45億米ドルから、予測期間中はCAGR 7%で推移し、2030年には63億米ドルに達すると予測されています。

当レポートでは、世界の関節リウマチ治療薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析などをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場サマリー

第2章 市場概要

• 概要
• マクロ経済要因の分析
• 米国の関税が製薬業界に与える影響
• 高齢化人口
• 地政学的リスク、貿易戦争、サプライチェーンの混乱
• 医療費の増加
• ポーターのファイブフォース分析

第3章 市場力学

• 市場力学
• 市場促進要因
• 関節リウマチ (RA) 治療におけるバイオシミラーの増加
• 関節リウマチ (RA) の症例数の増加
• 高齢化人口の増加
• 市場抑制要因
• 特許独占権の喪失
• リウマチ専門医の不足
• RA薬の副作用
• 市場機会
• RA治療における技術の進歩
• 新たな標的療法
• メーカーにおける無機戦略の増加

第4章 規制状況

• 概要
• 米国
• 生物学的製剤
• バイオシミラー
• 欧州
• アジア太平洋

第5章 新興技術とパイプライン分析

• 概要
• AIと機械学習 (ML)
• 幹細胞療法
• 免疫療法
• パイプライン分析
• 特許分析
• 重要ポイント

第6章 市場セグメンテーション分析

• セグメンテーションの内訳
• 世界のRA治療薬市場：治療タイプ別
• 重要ポイント
• 疾患修飾性抗リウマチ薬 (DMARD)
• 標的合成DMARD/JAK阻害剤
• 非ステロイド性抗炎症薬 (NSAID)
• バイオシミラー
• ステロイド
• その他
• 世界のRA治療薬市場：販売チャネル別
• 重要ポイント
• 処方薬
• 市販薬 (OTC)
• 地理的内訳
• 世界のRA治療薬市場：地域別
• 重要ポイント
• 北米
• 欧州
• アジア太平洋
• 中東・アフリカ
• 南米

第7章 競合情報

• 重要ポイント
• 市場シェア分析
• 企業シェア分析

第8章 RA治療薬市場における持続可能性：ESGの観点

• ESG：イントロダクション
• 関節リウマチ治療薬市場における持続可能性
• ESGの視点
• 環境への影響
• 社会的影響
• ガバナンスの影響
• ESGリスク評価
• 結論

第9章 付録

• 調査手法
• 略語
• 出典
• 企業プロファイル
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• PFIZER INC.
• SANOFI
• SWEDISH ORPHAN BIOVITRUM AB
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.

List of Tables

• Summary Table : Global Market for Rheumatoid Arthritis Therapies, by Region, Through 2030
• Table 1 : Current Health Expenditure
• Table 2 : Porter's Five Forces Analysis: RA Therapies Market
• Table 3 : Biosimilar Medicines for RA Treatment
• Table 4 : RA - Level 3 Cause, 2021
• Table 5 : Life Expectancy at Birth, by Country/Region, 2023
• Table 6 : Rheumatoid Arthritis - Level 3 Cause, 2021
• Table 7 : Commercially Available JAK Inhibitors
• Table 8 : Recent Strategic Partnerships in the RA Treatment Market
• Table 9 : Select Clinical Trials of RA Therapies
• Table 10 : Recent Patents Related to RA Therapies, 2025
• Table 11 : Global Market for RA Therapies, by Type, Through 2030
• Table 12 : Global Market for DMARDs in RA Therapies, by Type, Through 2030
• Table 13 : Global Market for Biologics in RA Therapies, by Type, Through 2030
• Table 14 : Global Market for DMARDs in RA Therapies, by Region, Through 2030
• Table 15 : Global Market for NSAIDs in RA Therapies, by Region, Through 2030
• Table 16 : Biosimilars for RA Treatment
• Table 17 : Global Market for Biosimilars in RA Therapies, by Region, Through 2030
• Table 18 : Global Market for Steroids in RA Therapies, by Region, Through 2030
• Table 19 : Global Market for Other Drugs in RA Therapies, by Region, Through 2030
• Table 20 : Global Market for RA Therapies, by Sales Channel, Through 2030
• Table 21 : Global Market for Prescription Drugs in RA Therapies, by Region, Through 2030
• Table 22 : Global Market for OTC Drugs in RA Therapies, by Region, Through 2030
• Table 23 : Global Market for RA Therapies, by Region, Through 2030
• Table 24 : North American Market for RA Therapies, by Type, Through 2030
• Table 25 : North American Market for DMARDs in RA Therapies, by Type, Through 2030
• Table 26 : North American Market for Biologics in RA Therapies, by Type, Through 2030
• Table 27 : North American Market for RA Therapies, by Sales Channel, Through 2030
• Table 28 : North American Market for RA Therapies, by Country, Through 2030
• Table 29 : U.S. Market for RA Therapies, by Type, Through 2030
• Table 30 : U.S. Market for RA Therapies, by Sales Channel, Through 2030
• Table 31 : Canadian Market for RA Therapies, by Type, Through 2030
• Table 32 : Canadian Market for RA Therapies, by Sales Channel, Through 2030
• Table 33 : Mexican Market for RA Therapies, by Type, Through 2030
• Table 34 : Mexican Market for RA Therapies, by Sales Channel, Through 2030
• Table 35 : European Market for RA Therapies, by Type, Through 2030
• Table 36 : European Market for DMARDs in RA Therapies, by Type, Through 2030
• Table 37 : European Market for Biologics in RA Therapies, by Type, Through 2030
• Table 38 : European Market for RA Therapies, by Sales Channel, Through 2030
• Table 39 : European Market for RA Therapies, by Country, Through 2030
• Table 40 : European Market for RA Therapies, by Country, Through 2030
• Table 41 : German Market for RA Therapies, by Type, Through 2030
• Table 42 : German Market for RA Therapies, by Sales Channel, Through 2030
• Table 43 : U.K. Market for RA Therapies, by Type, Through 2030
• Table 44 : U.K. Market for RA Therapies, by Sales Channel, Through 2030
• Table 45 : French Market for RA Therapies, by Type, through 2030
• Table 46 : French Market for RA Therapies, by Sales Channel, Through 2030
• Table 47 : Italian Market for RA Therapies, by Type, Through 2030
• Table 48 : Italian Market for RA Therapies, by Sales Channel, Through 2030
• Table 49 : Spanish Market for RA Therapies, by Type, Through 2030
• Table 50 : Spanish Market for RA Therapies, by Sales Channel, Through 2030
• Table 51 : Rest of European Market for RA Therapies, by Type, Through 2030
• Table 52 : Rest of European Market for RA Therapies, by Sales Channel, Through 2030
• Table 53 : Asia-Pacific Market for RA Therapies, by Type, Through 2030
• Table 54 : Asia-Pacific Market for DMARDs in RA Therapies, by Type, Through 2030
• Table 55 : Asia-Pacific Market for Biologics in RA Therapies, by Type, Through 2030
• Table 56 : Asia-Pacific Market for RA Therapies, by Sales Channel, Through 2030
• Table 57 : Asia-Pacific Market for RA Therapies, by Country, Through 2030
• Table 58 : Chinese Market for RA Therapies, by Type, Through 2030
• Table 59 : Chinese Market for RA Therapies, by Sales Channel, Through 2030
• Table 60 : Japanese Market for RA Therapies, by Type, Through 2030
• Table 61 : Japanese Market for RA Therapies, by Sales Channel, Through 2030
• Table 62 : Indian Market for RA Therapies, by Type, Through 2030
• Table 63 : Indian Market for RA Therapies, by Sales Channel, Through 2030
• Table 64 : South Korean Market for RA Therapies, by Type, Through 2030
• Table 65 : South Korean Market for RA Therapies, by Sales Channel, Through 2030
• Table 66 : Australian Market for RA Therapies, by Type, Through 2030
• Table 67 : Australian Market for RA Therapies, by Sales Channel, Through 2030
• Table 68 : Rest of Asia-Pacific Market for RA Therapies, by Type, Through 2030
• Table 69 : Rest of Asia-Pacific Market for RA Therapies, by Sales Channel, Through 2030
• Table 70 : MEA Market for RA Therapies, by Type, Through 2030
• Table 71 : MEA Market for DMARDs in RA Therapies, by Type, Through 2030
• Table 72 : MEA Market for Biologics in RA Therapies, by Type, Through 2030
• Table 73 : MEA Market for RA Therapies, by Sales Channel, Through 2030
• Table 74 : MEA Market for RA Therapies, by Region, Through 2030
• Table 75 : Middle East Market for RA Therapies, by Type, Through 2030
• Table 76 : Middle East Market for RA Therapies, by Sales Channel, Through 2030
• Table 77 : African Market for RA Therapies, by Type, Through 2030
• Table 78 : African Market for RA Therapies, by Sales Channel, Through 2030
• Table 79 : South American Market for RA Therapies, by Type, Through 2030
• Table 80 : South American Market for DMARDs in RA Therapies, by Type, Through 2030
• Table 81 : South American Market for Biologics in RA Therapies, by Type, Through 2030
• Table 82 : South American Market for RA Therapies, by Sales Channel, Through 2030
• Table 83 : South American Market for RA Therapies, by Country, Through 2030
• Table 84 : Brazilian Market for RA Therapies, by Type, Through 2030
• Table 85 : Brazilian Market for RA Therapies, by Sales Channel, Through 2030
• Table 86 : Argentinian Market for RA Therapies, by Type, Through 2030
• Table 87 : Argentinian Market for RA Therapies, by Sales Channel, Through 2030
• Table 88 : Rest of South American Market for RA Therapies, by Type, Through 2030
• Table 89 : Rest of South American Market for RA Therapies, by Sales Channel, Through 2030
• Table 90 : Key Focus Areas in ESG Metrics
• Table 91 : ESG Rankings for Leading Companies in the RA Therapies Market, 2024*
• Table 92 : Abbreviations Used in this Report.
• Table 93 : Report Sources
• Table 94 : Abbott: Company Snapshot
• Table 95 : Abbott: Financial Performance, FY 2023 and 2024
• Table 96 : Abbott: Product Portfolio
• Table 97 : AbbVie Inc.: Company Snapshot
• Table 98 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 99 : AbbVie Inc.: Product Portfolio
• Table 100 : Amgen Inc.: Company Snapshot
• Table 101 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 102 : Amgen Inc.: Product Portfolio
• Table 103 : Amgen Inc.: News/Key Development, 2023
• Table 104 : Bayer AG: Company Snapshot
• Table 105 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 106 : Bayer AG: Product Portfolio
• Table 107 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 108 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 109 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 110 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 111 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 112 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 113 : Gilead Sciences Inc.: Company Snapshot
• Table 114 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
• Table 115 : Gilead Sciences Inc.: Product Portfolio
• Table 116 : GSK plc.: Company Snapshot
• Table 117 : GSK plc.: Financial Performance, FY 2023 and 2024
• Table 118 : GSK plc.: Product Portfolio
• Table 119 : Johnson & Johnson Services Inc.: Company Snapshot
• Table 120 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
• Table 121 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 122 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
• Table 123 : Lilly: Company Snapshot
• Table 124 : Lilly: Financial Performance, FY 2023 and 2024
• Table 125 : Lilly: Product Portfolio
• Table 126 : Lilly: News/Key Development, 2024
• Table 127 : Pfizer Inc.: Company Snapshot
• Table 128 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 129 : Pfizer Inc.: Product Portfolio
• Table 130 : Pfizer Inc.: News/Key Developments, 2022-2025
• Table 131 : Sanofi: Company Snapshot
• Table 132 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 133 : Sanofi: Product Portfolio
• Table 134 : Swedish Orphan Biovitrum AB: Company Snapshot
• Table 135 : Swedish Orphan Biovitrum AB: Financial Performance, FY 2023 and 2024
• Table 136 : Swedish Orphan Biovitrum AB: Product Portfolio
• Table 137 : Swedish Orphan Biovitrum AB: News/Key Developments, 2023 and 2024
• Table 138 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 139 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 140 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 141 : Viatris Inc.: Company Snapshot
• Table 142 : Viatris Inc.: Financial Performance, FY 2023 and 2024
• Table 143 : Viatris Inc.: Product Portfolio
• Table 144 : Few Emerging Players in the Rheumatoid Arthritis Market

List of Figures

• Summary Figure : Global Market Shares of Rheumatoid Arthritis Therapies, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Market for RA Therapies
• Figure 2 : Market Dynamics of Rheumatoid Arthritis
• Figure 3 : Global Market Shares of RA Therapies, by Type, 2024
• Figure 4 : Global Market Shares of DMARDs in RA Therapies, by Type, 2024
• Figure 5 : Global Market Shares of Biologics in RA Therapies, by Type, 2024
• Figure 6 : Global Market Shares of DMARDs in RA Therapies, by Region, 2024
• Figure 7 : Global Market Shares of NSAIDs in RA Therapies, by Region, 2024
• Figure 8 : Global Market Shares of Biosimilars in RA Therapies, by Region, 2024
• Figure 9 : Global Market Shares of Steroids in RA Therapies, by Region, 2024
• Figure 10 : Global Market Shares of Other Drugs in RA Therapies, by Region, 2024
• Figure 11 : Global Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 12 : Global Market Shares of Prescription Drugs in RA Therapies, by Region, 2024
• Figure 13 : Global Market Shares of OTC Drugs in RA Therapies, by Region, 2024
• Figure 14 : Global Market Shares of RA Therapies, by Region, 2024
• Figure 15 : North American Market Shares of RA Therapies, by Type, 2024
• Figure 16 : North American Market Shares of DMARDs in RA Therapies, by Type, 2024
• Figure 17 : North American Market Shares of Biologics in RA Therapies, by Type, 2024
• Figure 18 : North American Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 19 : North American Market Shares of RA Therapies, by Country, 2024
• Figure 20 : U.S. Market Shares of RA Therapies, by Type, 2024
• Figure 21 : Canadian Market Shares of RA Therapies, by Type, 2024
• Figure 22 : Canadian Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 23 : Mexican Market Shares of RA Therapies, by Type, 2024
• Figure 24 : Mexican Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 25 : European Market Shares of RA Therapies, by Type, 2024
• Figure 26 : European Market Shares of DMARDs in RA Therapies, by Type, 2024
• Figure 27 : European Market Shares of Biologics in RA Therapies, by Type, 2024
• Figure 28 : European Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 29 : European Market Shares of RA Therapies, by Country, 2024
• Figure 30 : European Market Shares of RA Therapies, by Country, 2024
• Figure 31 : German Market Shares of RA Therapies, by Type, 2024
• Figure 32 : German Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 33 : U.K. Market Shares of RA Therapies, by Type, 2024
• Figure 34 : U.K. Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 35 : French Market Shares of RA Therapies, by Type, 2024
• Figure 36 : French Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 37 : Italian Market Shares of RA Therapies, by Type, 2024
• Figure 38 : Italian Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 39 : Spanish Market Shares of RA Therapies, by Type, 2024
• Figure 40 : Spanish Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 41 : Rest of European Market Shares of RA Therapies, by Type, 2024
• Figure 42 : Rest of European Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 43 : Asia-Pacific Market Shares of RA Therapies, by Type, 2024
• Figure 44 : Asia-Pacific Market Shares of DMARDs in RA Therapies, by Type, 2024
• Figure 45 : Asia-Pacific Market Shares of Biologics in RA Therapies, by Type, 2024
• Figure 46 : Asia-Pacific Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 47 : Asia-Pacific Market Shares of RA Therapies, by Country, 2024
• Figure 48 : Chinese Market Shares of RA Therapies, by Type, 2024
• Figure 49 : Chinese Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 50 : Japanese Market Shares of RA Therapies, by Type, 2024
• Figure 51 : Japanese Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 52 : Indian Market Shares of RA Therapies, by Type, 2024
• Figure 53 : Indian Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 54 : South Korean Market Shares of RA Therapies, by Type, 2024
• Figure 55 : South Korean Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 56 : Australian Market Shares of RA Therapies, by Type, 2024
• Figure 57 : Australian Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 58 : Rest of Asia-Pacific Market Shares of RA Therapies, by Type, 2024
• Figure 59 : Rest of Asia-Pacific Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 60 : MEA Market Shares of RA Therapies, by Type, 2024
• Figure 61 : MEA Market Shares of DMARDs in RA Therapies, by Type, 2024
• Figure 62 : MEA Market Shares of Biologics in RA Therapies, by Type, 2024
• Figure 63 : MEA Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 64 : MEA Market Shares of RA Therapies, by Region, 2024
• Figure 65 : Middle East Market Shares of RA Therapies, by Type, 2024
• Figure 66 : Middle East Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 67 : African Market Shares of RA Therapies, by Type, 2024
• Figure 68 : African Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 69 : South American Market Shares of RA Therapies, by Type, 2024
• Figure 70 : South American Market Shares of DMARDs in RA Therapies, by Type, 2024
• Figure 71 : South American Market Shares of Biologics in RA Therapies, by Type, 2024
• Figure 72 : South American Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 73 : South American Market Shares of RA Therapies, by Country, 2024
• Figure 74 : Brazilian Market Shares of RA Therapies, by Type, 2024
• Figure 75 : Brazilian Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 76 : Argentinian Market Shares of RA Therapies, by Type, 2024
• Figure 77 : Argentinian Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 78 : Rest of South American Market Shares of RA Therapies, by Type, 2024
• Figure 79 : Rest of South American Market Shares of RA Therapies, by Sales Channel, 2024
• Figure 80 : Leading 10 RA Products, by Sales Revenue, 2023-2024
• Figure 81 : Shares of the Global Market for RA Therapies, by Company, 2024
• Figure 82 : Pillars of ESG
• Figure 83 : Advantages of ESG for Companies
• Figure 84 : Abbott: Revenue Share, by Business Unit, FY 2024
• Figure 85 : Abbott: Revenue Share, by Region/Country, FY 2024
• Figure 86 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 87 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 88 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 89 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 90 : Bayer AG: Revenue Share, by Business Unit, FY 2024
• Figure 91 : Bayer AG: Revenue Share, by Country/Region, FY 2024
• Figure 92 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
• Figure 93 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
• Figure 94 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 95 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 96 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 97 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 98 : GSK plc.: Revenue Share, by Business Unit, FY 2024
• Figure 99 : GSK plc.: Revenue Share, by Country/Region, FY 2024
• Figure 100 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 101 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 102 : Lilly: Revenue Share, by Business Unit, FY 2024
• Figure 103 : Lilly: Revenue Share, by Country/Region, FY 2024
• Figure 104 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 105 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 106 : Sanofi: Revenue Share, by Business Unit, FY 2024
• Figure 107 : Sanofi: Revenue Share, by Country/Region, FY 2024
• Figure 108 : Swedish Orphan Biovitrum AB: Revenue Share, by Business Unit, FY 2024
• Figure 109 : Swedish Orphan Biovitrum AB: Revenue Share, by Country/Region, FY 2024
• Figure 110 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, 2024
• Figure 111 : Viatris Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 112 : Viatris Inc.: Revenue Share, by Country/Region, FY 2024

The global market for rheumatoid arthritis therapies was valued at $28.5 billion in 2024 and is estimated to increase from $30.2 billion in 2025 to reach $41.1 billion by 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

The North American market for rheumatoid arthritis therapies was valued at $15.5 billion in 2024 and is estimated to increase from $16.4 billion in 2025 to reach $22.4 billion by 2030, at a CAGR of 6.4% from 2025 through 2030.

The Asia-Pacific market for rheumatoid arthritis therapies was valued at $4.2 billion in 2024 and is estimated to increase from $4.5 billion in 2025 to reach $6.3 billion by 2030, at a CAGR of 7% from 2025 through 2030.

Report Scope

The current report will provide detailed information on therapies for rheumatoid arthritis (RA). This report analyzes the market trends of RA therapies, with the base year for the study set at 2024, estimated for 2025, and forecast between 2026 and 2030, including compound annual growth rate (CAGR) for the forecast period and regional markets. The report will highlight current and future market potential and provide a detailed analysis of the competitive environment as well as regulatory scenarios, drivers, restraints, and opportunities. The report also covers the market shares for key producers.

The market scope in this report is segmented into therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), steroids/corticosteroids, biosimilars, and others. It also covers over-the-counter (OTC)- and prescription-based sales channels.

The report covers significant geographical regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The regional segmentation will offer a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 through 2030.

The report aims to:

• Analyze RA therapy types.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness, and industry structure.
• Identify potential long-term impacts on the market for RA therapies.

Report Includes

• 94 data tables and 51 additional tables
• In-depth analysis of the global markets for rheumatoid arthritis (RA) treatment therapies
• Analyses of global market trends, with revenue data for 2024, estimates for 2025, forecasts for 2026, and projected CAGRs through 2030
• Estimates of the market's current size and revenue prospects, accompanied by a market share analysis based on therapy type, sales channel and region
• Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
• Insights derived from Porter's Five Forces model, as well as global supply chain analysis
• Discussion of the key marketed products and products in different stages of clinical development
• An analysis of patents, and emerging trends and developments in patent activity
• Overview of sustainability trends and ESG developments, with consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including AbbVie Inc., Pfizer Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Co., Amgen Inc., and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Macroeconomic Factor Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Aging Population
• Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
• Increasing Healthcare Expenditures
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Biosimilars for RA Treatment
• Rising Cases of RA
• Increasing Aging Population
• Market Restraints
• Loss of Patent Exclusivity
• Shortage of Rheumatologists
• Side Effects of RA Drugs
• Market Opportunities
• Technological Advances in RA Therapies
• Emerging Targeted Therapies
• Increasing Inorganic Strategies amongst Manufacturers

Chapter 4 Regulatory Landscape

• Overview
• The U.S.
• Biologics
• Biosimilars
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence (AI) and Machine Learning (ML)
• Stem Cell Therapy
• Immunotherapy
• Pipeline Analysis
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for RA Therapies by Therapy Type
• Key Takeaways
• Disease-modifying Anti-rheumatic Drugs (DMARDs)
• Targeted Synthetic DMARDs/JAK Inhibitors
• Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
• Biosimilars
• Steroids
• Other Drugs
• Global RA Therapies by Sales Channel
• Key Takeaways
• Prescription Drugs
• Over-the-Counter (OTC) Drugs
• Geographic Breakdown
• Global Market for RA Therapies, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa (MEA)
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Share Analysis
• Company Share Analysis

Chapter 8 Sustainability in the RA Therapies Market: An ESG Perspective

• Introduction to ESG
• Sustainability in the Market for RA Therapies
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• PFIZER INC.
• SANOFI
• SWEDISH ORPHAN BIOVITRUM AB
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC.